title: Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers.
abstract: The aim of the present study was to investigate whether CYP2C19 polymorphism status and gastric emptying are related to healing in patients with gastric ulcers. We studied the CYP2C19 status in seven patients with proton pump inhibitor (PPI)-resistant ulcers, 21 with PPI-sensitive ulcers and 46 healthy volunteers using polymerase chain reaction restriction fragment length polymorphism to detect CYP2C19m1 mutation in exon 5 and CYP2C19m2 mutation in exon 4. Gastric emptying was evaluated using the 13C-acetate breath test. The frequency of phenotypes, indicated by genotypes, did not differ significantly between the three patient groups. The peak time of 13C excretion in patients with PPI-resistant ulcers was significantly longer than that of patients with PPI-sensitive ulcers and healthy volunteers. Our results suggest that rate of gastric emptying, but not CYP2C19 polymorphism, is likely to be an important factor in the delayed healing of patients with PPI-resistant gastric ulcer.
authors.affiliation: Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan.
authors.forename: F
authors.initials: F
authors.lastname: Wada
authors.forename: K
authors.initials: K
authors.lastname: Murase
authors.forename: H
authors.initials: H
authors.lastname: Isomoto
authors.forename: H
authors.initials: H
authors.lastname: Soda
authors.forename: F
authors.initials: F
authors.lastname: Takeshima
authors.forename: K
authors.initials: K
authors.lastname: Omagari
authors.forename: Y
authors.initials: Y
authors.lastname: Mizuta
authors.forename: K
authors.initials: K
authors.lastname: Tsukamoto
authors.forename: I
authors.initials: I
authors.lastname: Murata
authors.forename: S
authors.initials: S
authors.lastname: Kohno
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000502:physiology; D001562:Benzimidazoles / Q000627:therapeutic use; D065731:Cytochrome P-450 CYP2C19; D005260:Female; D005746:Gastric Emptying / Q000235:genetics / Q000502:physiology*; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000235:genetics* / Q000502:physiology; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011110:Polymorphism, Genetic / Q000502:physiology; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D013276:Stomach Ulcer / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics* / Q000503:physiopathology
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D064750:Rabeprazole; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D009853:Omeprazole